The National Innovation Strategy is Closely Related to Enterprise Development

Now the China’s economy development receives lots of attention, especially the innovation. It is expected that the government will make efforts to promote innovation in the future, and the government has actually done something to promote innovation. The guidance to big health is clear in the 2030 national strategy, which drives the high-speed promotion of big health industry in China, and we believe there will be better opportunity ion the future.

With over 20 years of development, Fosun Pharma has developed its business in research & development and manufacturing of drug, medical device, medical diagnosis and medical service fields and become the company covering the whole big health industry chain. We have two core businesses at present:

1. Innovation-driven R&D manufacturing, focusing on pharmacy, medical device and medical diagnosis;

2. Provision of more efficient medical treatment and medicine service supply chain, including hospital and drug store service.

Accurate medical treatment is an important development direction for big health industry in the future, and with the leading R&D capacity, the comprehensive drug R&D, treatment means and health service innovation can be realized to create accurate medical closed loop.

Pharmacy is the everlasting key. Chemical drug was the main drug introduced to China during the early introduction of western medicine and biological agent. Biological medicine is still expensive. Globally, diseases like cancer can be divided into micromolecule and macromolecule. The targeted drug for macromolecule is developed for specific target based on the present understanding to the relation between gene and disease. Absolutely, most of the drugs under research and development in medical companies in the world are related to the target.

The innovation ability should be in line with the global ability